Navigation Links
Telik's Aurora Kinase-VEGFR Dual Inhibitor Program Meets a Preclinical Development Milestone
Date:8/21/2008

PALO ALTO, Calif., Aug. 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that the lead compounds of its Aurora kinase and VEGFR dual inhibitor program met a significant development milestone. Aurora kinase is a critical signaling enzyme whose function is required for cancer cell division, while vascular endothelial growth factor receptor (VEGFR) plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. Telik's lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR. A development drug candidate is being selected, and assuming successful completion of preclinical studies, a Phase 1 clinical study may be initiated.

"Our computational TRAP(R) technology enabled us to combine and process information on the properties of single target molecules resulting in compounds with the desired dual target mechanism of action," said Steve Schow, Ph.D., Vice President of Research at Telik. "The ability to inhibit two targets may reduce the ability of cancer cells to evade the inhibition of one target alone and results in a better outcome."

The initial data demonstrating the activity of Telik's lead compounds was presented at the EORTC-AACR-NCI Meeting held in Belgium in the fourth quarter of 2007.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemothera
'/>"/>

SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
2. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
3. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
6. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
7. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
8. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
9. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
10. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
11. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  Lisa Kulik saw fireworks for the first time ... to a groundbreaking retinal implant co-invented by Mark ... the University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative ... June 2, she became the first person west of ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... 27, 2014 After the boom of ... the next beverage craze is going to be the ... formulators can use Stress Relief energy pattern which can ... making of a beverage, including minerals, herbs and liquids. ... channeling that power into rapid recovery and helping to ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... the first televised debate in Wisconsin's campaign for governor came ... Gov. Jim Doyle and challenger Mark Green ... who had worked for Pabst Brewery before its 1997 cutbacks, ... all over the place" - and he wanted to know ...
... Blood and Marrow Transplant Research at the Medical ... to collect and analyze standardized data on the outcomes of ... or cord blood. , ,The Health Resources and Services ... and Human Services , awarded the funds through the Stem ...
... Madison, Wis. - In the fossil fuels economy, Wisconsin ... coal under the state's rolling terrain, so millions of dollars ... "beneficiary" states and nations of our fossil fuel age. , ... best efforts of its businesses, governments, and citizens to conserve. ...
Cached Biology Technology:Candidates' sparring over jobs focuses debate on right issue 2Candidates' sparring over jobs focuses debate on right issue 3Medical College to build $6M transplant database 2State should keep open mind on nuclear power 2State should keep open mind on nuclear power 3State should keep open mind on nuclear power 4
(Date:8/27/2014)... is related to ability that we already possess. For ... more easily than learning how to hit a tennis ... Neural Basis of Cognition (CNBC)a joint program between the ... fundamental constraint in the brain that may explain why ... Aug. 28, 2014, issue of Nature , they ...
(Date:8/27/2014)... Athens, Ga. An invasive grass species frequently found ... spiders, who then feed on American toads, a new ... which was accidentally introduced to the U.S. in the ... species and has spread to more than a dozen ... Typically found along roads and in forests, it can ...
(Date:8/27/2014)... When we want to listen carefully to someone, the ... thing we do is stop moving altogether. This strategy ... by our own movements. , This interplay between movement ... brain. Indeed, indirect evidence has long suggested that the ... auditory cortex, which gives rise to our conscious perception ...
Breaking Biology News(10 mins):Pitt and Carnegie Mellon engineers discover why learning can be difficult 2Pitt and Carnegie Mellon engineers discover why learning can be difficult 3More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3
... College chemists have discovered a substance that will make ... and other chemicals in a faster, less expensive way. ... issue of the journal Nature, a team led by ... College Chemistry Department said they had found a first-of-its-kind ...
... TGF-beta has been shown to suppress the growth of tumor ... of TGF-beta during the later stages of the disease are ... cancer samples and mice, which appears online on December 7 ... the Journal of Clinical Investigation, indicates that changes in expression ...
... In a paper published yesterday in The Proceedings ... from Boston University School of Dental Medicine generated ... Boston University researchers found that the transcription factor ... a completely different pathway than the better known ...
Cached Biology News:BC catalyst discovery promises faster, cheaper drug production 2
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Propidium Iodide: {3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diodide}. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 2.5ug/mL Propidium Iodide (PI)...
Detects caspase activation by flow cytometry....
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Biology Products: